Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis

Jonathan I. Silverberg(George Washington University), Christopher G. Bunick(Yale University), Wan‐Ju Lee, Andrew Pink, Valéria Aoki(Universidade de São Paulo), Yousef Binamer(Alfaisal University), Norito Katoh(Kyoto Prefectural University of Medicine), Brian Calimlim(AbbVie (United States)), Shawn G. Kwatra(University of Maryland, Baltimore), Alvaro Moreira(Icahn School of Medicine at Mount Sinai), Andreas Wollenberg(University Hospital Augsburg), Ayman Grada(University Hospitals of Cleveland), Diego Ruiz Dasilva(Eastern Virginia Medical School), Chao Li(Eli Lilly (United States)), Melinda Gooderham(Queen's University)
Dermatology and Therapy
June 26, 2025
10.1007/s13555-025-01469-0
Cited by 9

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516